Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pharmsville Co (318010) Fair Value & Analysis

Healthcare · KR · Market cap 27.1B KRW

Price3,330 KRW
Fair Value5,233 KRW
Upside+57.1%
Quality95/100
Evidence: High Range 3,925 KRW – 6,530 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Pharmsville Co (318010) currently trades at 3,330 KRW, while our model-based Fair Value estimate is 5,233 KRW — implying the stock looks roughly 57.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Pharmsville Co., Ltd. produces and sells functional health food in South Korea. The company also exports its products. It offers its products under the Apple Tree Dr. Kim, Devil Diet, Sang Sang Bang, Vitamin Story, Apple Tree, Golden Garden, Daily Green, Wilac, Doctor Solution, and PS brands. Pharmsville Co., Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Pharmsville Co (318010) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 5,233 KRW versus a price of 3,330 KRW — about +57% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 318010?
Our 21-model fair value for Pharmsville Co is 5,233 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 3,330 KRW.
What is the quality score of 318010?
Pharmsville Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.